What is Cellomics Technology?
Cellomics Technology, LLC is a specialized provider of innovative tools for gene editing and delivery, with a primary focus on mammalian cell gene engineering. The company offers a comprehensive suite of products, including a diverse range of lentiviral vectors, essential cell culture reagents, and bespoke services tailored for gene targeting and the generation of stable cell lines. Cellomics Technology is dedicated to empowering researchers in somatic and stem cell genetic engineering by supplying high-quality products and expert services, catering to scientists and investigators in molecular biology and genetic engineering.
How much funding has Cellomics Technology raised?
Cellomics Technology has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2024): $150K with participation from Bank of America
Key Investors in Cellomics Technology
Bank of America
Bank of America is a leading global financial institution. Their participation in this funding round, categorized as debt, suggests a role in providing crucial financial infrastructure and capital to support Cellomics Technology's operational scaling and strategic initiatives.
What's next for Cellomics Technology?
The substantial large-scale late-stage funding positions Cellomics Technology for accelerated growth and market expansion. This strategic investment is likely to fuel further research and development into novel gene editing technologies, enhance production capabilities for their lentiviral vectors and reagents, and broaden their service offerings. The company is poised to solidify its role as a key enabler for cutting-edge genetic research and therapeutic development, leveraging this capital to deepen its impact in the biotechnology sector.
See full Cellomics Technology company page
